Peptide-based targeting of the platelet-derived growth factor receptor beta

Molecular Imaging and Biology

Volumn 15, Issue 2, 2013, Pages 212-221

  Askoxylakis, Vasileios ^a   Marr, Annabell ^a   Altmann, Annette ^a   Markert, Annette ^a   Mier, Walter ^a   Debus, Jürgen ^a   Huber, Peter E ^a   Haberkorn, Uwe ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Peptide ligand; Phage display; Targeting

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; BIOPANNING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; MOLECULAR DYNAMICS; ORGAN DISTRIBUTION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN LOCALIZATION; PROTEIN TARGETING;

MUS MUSCULUS;

EID: 84878490645     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0578-7     Document Type: Article

References (35)

1. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276-1312
2. Betsholtz C, Karlsson L, Lindahl P (2001) Developmental roles of platelet-derived growth factors. Bioessays 23:494-507
3. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
4. Lindahl P, Hellstrom M, Kalen M et al (1998) Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice. Curr Opin Lipidol 9:407-411
5. Shen J, Vil MD, Prewett M et al (2009) Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11:594-604
6. Pietras K, Rubin K, Sjoblom T et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484
7. Klosowska-Wardega A, Hasumi Y, Burmakin M et al (2009) Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One 4:e8149
8. Starling N, Hawkes EA, Chau I et al (2012) A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Ann Oncol 23:942-947.
9. Abdollahi A, Lipson KE, Han X et al (2003) SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63:3755-3763
10. Weigel MT, Dahmke L, Schem C et al (2010) In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 10:412
11. Abdollahi A, Li M, Ping G et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925-935
12. Paulsson J, Sjoblom T, Micke P et al (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334-341
13. Hägglöf C, Hammarsten P, Josefsson A et al (2010) Stromal PDGFRβ expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One 5:e10747
14. Dagher R, Cohen M, Williams G et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038
15. Roberts WG, Whalen PM, Soderstrom E et al (2005) Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 65:957-966
16. Ramakrishnan V, Escobedo MA, Fretto LJ et al (1993) A novel monoclonal antibody dependent on domain 5 of the platelet-derived growth factor beta receptor inhibits ligand binding and receptor activation. Growth Factors 8:253-265
17. Mabry R, Gilbertson DG, Frank A et al (2010) A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2:20-34
18. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814s-819s
19. Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104-111
20. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146
21. Haberkorn U, Eisenhut M, Altmann A et al (2008) Endoradiotherapy with peptides - status and future development. Curr Med Chem 15:219-234
22. Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112:1142-1151
23. George D (2001) Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 28:27-33
24. Lindborg M, Cortez E, Hoiden-Guthenberg I et al (2011) Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 407:298-315
25. Chung HW, Wen J, Lim JB et al (2009) Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. Int J Radiat Oncol Biol Phys 75:862-869
26. Askoxylakis V, Garcia-Boy R, Rana S et al (2010) A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One 5:e15962
27. Askoxylakis V, Zitzmann-Kolbe S, Zoller F et al (2011) Challenges in optimizing a prostate carcinoma binding peptide, identified through the phage display technology. Molecules 16:1559-1578
28. Powell DW, Mifflin RC, Valentich JD et al (1999) Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277:C183-C201
29. Fischer PM (2003) The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 4:339-356
30. John H, Maronde E, Forssmann WG et al (2008) N-terminal acetylation protects glucagon-like peptide GLP-1-[7-34]-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. Eur J Med Res 13:73-78
31. Lee SH, Lee S, Youn YS et al (2005) Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 16:377-382
32. Boy RG, Mier W, Nothelfer EM et al (2010) Sunflower trypsin inhibitor 1 derivatives as molecular scaffolds for the development of novel peptidic radiopharmaceuticals. Mol Imaging Biol 12:377-385
33. Yan Y, Chen X (2011) Peptide heterodimers for molecular imaging. Amino Acids 41:1081-1092
34. Crim JW, Garczynski SF, Brown MR (2002) Approaches to radioiodination of insect neuropeptides. Peptides 23:2045-2051
35. Askoxylakis V, Mier W, Zitzmann S et al (2006) Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. J Nucl Med 47:981-988